From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

Drug-induced liver injury (DILI) is a frequent cause of acute liver failure and drug withdrawals. Liver organoids, as a ...

Lab-grown organs, also known as organoids, are progressing from lab research toward clinical application. This article ...

Organoid and organ-on-a-chip technologies represent a transformative leap in the field of biomedical science. Historically, traditional in vitro methods ...

Get our top picks of the posters at AACR 2025 and learn more about the method behind them and the techniques used.

Researchers have created a groundbreaking 3D-printed artificial tumor tissue capable of replicating the in vivo conditions of ...

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) were trading at $30.25, down $5.60, or 15%, on word of the delay of data from the phase III X-tole2 trial with azetukalner in focal onset seizures ...

Q3 2025 Earnings Call Transcript May 7, 2025 Bio-Techne Corporation beats earnings expectations. Reported EPS is $0.56, expectations were $0.51. Operator: Good morning and welcome to the Bio-Techne ...

One approach is to use antibody-drug conjugates (ADCs), which combine ... Instead, GSK is using a biological model of a tumor called an organoid as an efficient way to represent this complex ...

By refining organoid derivation methods, scientists can create more accurate cancer models, enhancing drug screening processes and paving the way for more personalized and effective treatment ...

Over 95% of potential anti-cancer drugs failed in clinical trials despite vast investment to bring the drug to market. The last decade of cancer research has also seen numerous advances aimed at ...